in2it a bright spot in difficult year for Provalis' diagnostics
This article was originally published in Clinica
In what has been described as a "challenging year", Provalis saw its 2004 medical diagnostic revenues take a nosedive, reaching only £1.5m ($2.7m), compared with last year's strong performance of £3.1m. However, the UK company believes that with its new in2it diabetes diagnostic product poised for commercialisation and a direct sales operation in the US now established, the groundwork has been set for driving strong diagnostic revenues and profits in the forthcoming years.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.